You are here

Enhanced Fluoropolymer Membrane Reactors for Production of Pharmaceutical Interme

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43RR032260-01
Agency Tracking Number: R43RR032260
Amount: $396,124.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCRR
Solicitation Number: PA10-122
Solicitation Year: 2011
Award Year: 2011
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
335 Water Street
Newport, DE 19804-
United States
DUNS: 808898894
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (302) 999-7996
Business Contact
Phone: (302) 999-7996
Research Institution

DESCRIPTION (provided by applicant): The commercial syntheses of many pharmaceutical active ingredients and intermediates require acid catalysts and the removal of water to drive reactions to completion. Typical reactions include esterifications of carboxylic acids with alcohols, Friedel-Crafts acylations and alkylations, Schiff base, acetal and ketal formation and nitrations of aromatic compounds. Although common mineral acids are typically employed as catalysts, they create issues with product purification, waste disposal, safety, the environment and homeland security. Compact Membrane Systems, Inc. (CMS) proposes to develop membrane reactors (MR) to enhance these processes and eliminate the problems created by existing acid catalysts. CMS proposes developing enhanced membrane reactors and demonstrating performance on relevant pharmaceutical reactants. CMS has obtained key industry experts to facilitate this program. In this program, CMS will fabricate the membrane reactors. The resultant MR will be used torun reactions of pharmaceutical interest such as the alkylation and nitration of aromatic compounds. Expectation is that the CMS membrane reactor will result in higher yields, faster reactions and less contaminated products relative to incumbent processesand will have a very long lifetime due to the perfluorinated nature of the polymer. Society will benefit due to the lower production costs for the products, option for synthesis at lower temperature to maximize API efficacy, minimization of waste productsand elimination of the transport and storage of strong mineral acids. PUBLIC HEALTH RELEVANCE: Project Narrative The use of catalytic membrane reactors can replace acid catalysts in the synthesis of pharmaceutical products at lower cost and higherprocessing throughput.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government